Zaire Ebola Vaccines Produce Antibody Responses as Early as 14 Days
Three vaccine regimens for Zaire Ebola virus disease (EVD) produced antibody responses in adults and children, according to the results of two randomized trials conducted in West Africa. At 12 months, 41% of adults and 78% of children had a response to the Ad26-MVA regimen (Ad26.ZEBOV followed by MVA-BN-Filo 56 days later), 76% and 87% […]
Monoclonals for COVID in Pregnancy Pass Safety Test, Efficacy on the Other Hand …
Monoclonal antibody treatment for COVID-19 was safe to use in pregnancy, but wasn’t all that effective, according to a single-center study. Among pregnant patients with mild-to-moderate COVID-19 who received monoclonal antibody treatment, infusion reactions were rare, with 1.4% of patients experiencing mild, drug-related adverse events (AEs), reported Erin McCreary, PharmD, of University of Pittsburgh Medical […]
Monoclonal Antibody Shows Protection Against Malaria
SEATTLE — A monoclonal antibody delivered intravenously was effective in protecting against Plasmodium falciparum infection over a 6-month malaria season in Mali, a phase II placebo-controlled trial showed. Among 330 healthy adults, P. falciparum infection was detected in 35.5% who received a single dose of CIS43LS 10 mg/kg, 18.2% who received a 40-mg/kg dose, and […]
COVID Antivirals Appear to Hold Up Against BA.2
While two monoclonal antibody combinations showed neutralizing activity against the Omicron subvariant BA.2, both required substantially higher concentrations to produce a response in patients with COVID-19, Japanese researchers said, while antivirals appeared to be less affected. Casirivimab/imdevimab (REGEN-COV) and tixagevimab/cilgavimab (Evusheld) inhibited BA.2, but the titer of monoclonal antibodies “required for a 50% reduction in […]
Targeting IL-23 Succeeds in Psoriatic Arthritis
The monoclonal antibody risankizumab (Skyrizi) showed significant efficacy for psoriatic arthritis (PsA) in two phase III randomized trials, a researcher reported. In the KEEPSAKE 1 and 2 trials, 1,407 patients with active PsA were randomly assigned to receive subcutaneous risankizumab, 150 mg, or placebo at baseline and then at weeks 4 and 16. On the […]
COVID Prevention Tx Safe, Shows Efficacy in High-Risk Groups
A monoclonal antibody cocktail designed for COVID-19 pre-exposure prophylaxis was safe, and appeared to be effective across populations at risk of severe COVID and who may have a subpar response to vaccination, a researcher said. AZD7442 (tixagevimab/cilgavimab) met its primary endpoint, reducing the risk of symptomatic COVID-19 among high-risk populations by 77% (95% CI 46%-90%), […]
Bispecific Antibody Shows Promise in R/R Multiple Myeloma
Teclistamab, a bispecific antibody that binds B-cell maturation antigen (BCMA) and CD3 to redirect T cells to multiple myeloma cells, showed promising efficacy in patients with relapsed or refractory disease, according to results from a phase I study. Forty patients received the recommended phase II dose of subcutaneous teclistamab, which led to an overall response […]
Monoclonal antibody may prevent malaria
One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The small, carefully monitored clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people. The trial […]
Monoclonal Antibody Cocktail Authorized for Post-COVID Exposure
FDA expanded the emergency use authorization (EUA) for the monoclonal antibody cocktail casirivimab and imdevimab, to include post-exposure prophylaxis (PEP) among certain people exposed to COVID-19, manufacturer Regeneron announced on Friday. Casirivimab-imdevimab (REGEN-COV) is the first monoclonal antibody treatment that can be used either as a treatment for COVID-19 or after exposure but prior to […]
What Is the Normal Range for Hepatitis B Surface Antibody?
Learn about how the hepatitis B surface antibody test works, and how its results indicate immunity to the virus Hepatitis B surface antibodies (anti-HBs or HBsAb) are measured in blood samples in milli-International Units/milliliter mIU/mL). The ranges for hepatitis B surface antibodies are: Anti-HBs greater than 10-12 mIU/mL: Protected against hepatitis B virus (HBV) infection, […]